Marlborough, MA, April 24, 2017 – Proveris Scientific Corporation, a leading organization engaged in advancing the science of nasal and inhaled drug delivery, has joined The International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as an associate member.

IPAC-RS is a highly respected technical resource and industry advocate for enhancing product quality for the benefit of patients who use orally inhaled and nasal drug products (OINDPs) to treat asthma, COPD and other respiratory diseases.
As an IPAC-RS Associate Member, Proveris and related member experts will collaborate in technical feasibility groups, knowledge networks and working groups related to the regulatory science of OINDPs. Proveris will participate in a wide range of IPAC-RS working groups from technology advancements to global regulatory review and outreach to emerging areas in India and China.

“We are excited to join IPAC-RS and have our team of experts positively contribute to advancing the global regulatory science of OINDPs via IPAC-RS working groups, technical committees and presentations, and outreach to rapidly developing regions such as India and China,” says Dino Farina, CEO of Proveris Scientific. “We hope to bring to the IPAC-RS community our 20+ years of collective experience working closely with generic and branded pharmaceutical companies, device suppliers, and global regulatory agencies that have provided us a unique perspective on some of the critical challenges that face our industry and how to bridge the knowledge gaps between patient use, formulation, device and regulatory compliance.
“IPAC-RS welcomes Proveris as an Associate Member. From our earliest days as a consortium, we have appreciated the perspectives and engagement of our supplier members and we look forward to Proveris’ involvement.” says Robert Berger, IPAC-RS Chair.


IPAC-RS is an international association that seeks to advance the science, and especially the regulatory science, of orally inhaled and nasal drug products (OINDP) by collecting and analyzing data, and conducting joint research and development projects. Their members include innovator and generic companies that develop, manufacture or market orally inhaled and nasal drug products for local and systemic treatment of a variety of debilitating diseases such as asthma, chronic obstructive pulmonary disease and diabetes. The association aims to build consensus and contribute to effective regulations and standards by sharing the results of our research through conferences, technical journals, and discussions with regulatory bodies.

About Proveris Scientific Corporation

Proveris Scientific Corporation advances the science of nasal and inhaled drug delivery by providing leading technology in spray performance measurement, unrivaled accuracy in automated actuation, and expertise in drug-device optimization. Since its founding in 1995, the company has accelerated the development of 5 of the top 7 spray drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2008 by TUV Rheinland of North America and has more than 20 patents on its technology issued in United States, Europe, and Asia. For more information, please visit information, please visit